

SOUTHERN MEDICAL ASSOCIATION

**Your
CME Resource**

CLINICAL UPDATE 1997

**AUGUST 15-17, 1997
SONESTA BEACH RESORT
KEY BISCAYNE, FLORIDA**

**FEATURING
SPECIALTY TRACKS ON:**



**Orthopaedic Surgery
Radiology**

**Rheumatology
Geriatrics**

**Primary Care physicians can also take advantage of this
specialty clinical update!**

The Southern Medical Association is accredited by the Accreditation Council for Continuing Medical Education to sponsor continuing medical education for physicians.

For more information or to register, please call 800-423-4992.

In hypertension

HE KNOWS THE PROOF
IS IN THE PERFORMANCE



THAT'S WHY HE
PRESCRIBES ADALAT CC

Efficacy comparable to Procardia XL^{®1,2}
and Norvasc^{®*3,4}

Similar safety profile[†] to Procardia XL^{1,3}
and Norvasc^{3,4}

Substantially lower cost than Procardia XL
and Norvasc^{‡5}

Once-A-Day

Adalat[®]CC
nifedipine EXTENDED
RELEASE
TABLETS

30mg, 60mg & 90mg

A PRACTICAL CHOICE

Adalat CC is not indicated for angina. It should be taken on an empty stomach. As with all distinct pharmacologic entities, switching from one to another may necessitate careful titration and patient monitoring.

*Procardia XL (nifedipine) and Norvasc (amlodipine besylate) are registered trademarks of Pfizer Labs Division, Pfizer Inc.

†Frequency and type of side effects are typical of dihydropyridine calcium channel blockers.⁶

‡Calculations based on suggested Average Wholesale Price (AWP).⁵ AWP is from a published price list and may or may not represent the actual price to pharmacists or consumers.

Please see brief summary of Prescribing Information on following page.

Once-A-Day

Adalat[®] CC

nifedipine

EXTENDED
RELEASE
TABLETS

30mg, 60mg & 90mg

A PRACTICAL CHOICE

BRIEF SUMMARY CONSULT PACKAGE INSERT FOR FULL PRESCRIBING INFORMATION For Oral Use

PZ500046BS

9/96

INDICATION AND USAGE: ADALAT CC is indicated for the treatment of hypertension. It may be used alone or in combination with other antihypertensive agents.

CONTRAINDICATIONS: Known hypersensitivity to nifedipine.

WARNINGS: Excessive Hypotension: Although in most patients the hypotensive effect of nifedipine is modest and well tolerated, occasional patients have had excessive and poorly tolerated hypotension. These responses have usually occurred during initial titration or at the time of subsequent upward dosage adjustment, and may be more likely in patients using concomitant beta-blockers.

Severe hypotension and/or increased fluid volume requirements have been reported in patients who received immediate release capsules together with a beta-blocking agent and who underwent coronary artery bypass surgery using high dose fentanyl anesthesia. The interaction with high dose fentanyl appears to be due to the combination of nifedipine and a beta-blocker, but the possibility that it may occur with nifedipine alone, with low doses of fentanyl, in other surgical procedures, or with other narcotic analgesics cannot be ruled out. In nifedipine-treated patients where surgery using high dose fentanyl anesthesia is contemplated, the physician should be aware of these potential problems and, if the patient's condition permits, sufficient time (at least 36 hours) should be allowed for nifedipine to be washed out of the body prior to surgery.

Increased Angina and/or Myocardial Infarction: Rarely, patients, particularly those who have severe obstructive coronary artery disease, have developed well documented increased frequency, duration and/or severity of angina or acute myocardial infarction upon starting nifedipine or at the time of dosage increase. The mechanism of this effect is not established.

Beta-Blocker Withdrawal: When discontinuing a beta-blocker it is important to taper its dose, if possible, rather than stopping abruptly before beginning nifedipine. Patients recently withdrawn from beta blockers may develop a withdrawal syndrome with increased angina, probably related to increased sensitivity to catecholamines. Initiation of nifedipine treatment will not prevent this occurrence and on occasion has been reported to increase it.

Congestive Heart Failure: Rarely, patients (usually while receiving a beta-blocker) have developed heart failure after beginning nifedipine. Patients with tight aortic stenosis may be at greater risk for such an event, as the unloading effect of nifedipine would be expected to be of less benefit to these patients, owing to their fixed impedance to flow across the aortic valve.

PRECAUTIONS: General - Hypotension: Because nifedipine decreases peripheral vascular resistance, careful monitoring of blood pressure during the initial administration and titration of ADALAT CC is suggested. Close observation is especially recommended for patients already taking medications that are known to lower blood pressure (See WARNINGS).

Peripheral Edema: Mild to moderate peripheral edema occurs in a dose-dependent manner with ADALAT CC. The placebo subtracted rate is approximately 8% at 30 mg, 12% at 60 mg and 19% at 90 mg daily. This edema is a localized phenomenon, thought to be associated with vasodilation of dependent arterioles and small blood vessels and not due to left ventricular dysfunction or generalized fluid retention. With patients whose hypertension is complicated by congestive heart failure, care should be taken to differentiate this peripheral edema from the effects of increasing left ventricular dysfunction.

Information for Patients: ADALAT CC is an extended release tablet and should be swallowed whole and taken on an empty stomach. It should not be administered with food. Do not chew, divide or crush tablets.

Laboratory Tests: Rare, usually transient, but occasionally significant elevations of enzymes such as alkaline phosphatase, CPK, LDH, SGOT, and SGPT have been noted. The relationship to nifedipine therapy is uncertain in most cases, but probable in some. These laboratory abnormalities have rarely been associated with clinical symptoms; however, cholestasis with or without jaundice has been reported. A small increase (<5%) in mean alkaline phosphatase was noted in patients treated with ADALAT CC. This was an isolated finding and it rarely resulted in values which fell outside the normal range. Rare instances of allergic hepatitis have been reported with nifedipine treatment. In controlled studies, ADALAT CC did not adversely affect serum uric acid, glucose, cholesterol or potassium.

Nifedipine, like other calcium channel blockers, decreases platelet aggregation *in vitro*. Limited clinical studies have demonstrated a moderate but statistically significant decrease in platelet aggregation and increase in bleeding time in some nifedipine patients. This is thought to be a function of inhibition of calcium transport across the platelet membrane. No clinical significance for these findings has been demonstrated.

Positive direct Coombs' test with or without hemolytic anemia has been reported but a causal relationship between nifedipine administration and positivity of this laboratory test, including hemolysis, could not be determined.

Although nifedipine has been used safely in patients with renal dysfunction and has been reported to exert a beneficial effect in certain cases, rare reversible elevations in BUN and serum creatinine have been reported in patients with pre-existing chronic renal insufficiency. The relationship to nifedipine therapy is uncertain in most cases but probable in some.

Drug Interactions: Beta-adrenergic blocking agents: (See WARNINGS).

ADALAT CC was well tolerated when administered in combination with a beta blocker in 187 hypertensive patients in a placebo-controlled clinical trial. However, there have been occasional literature reports suggesting that the combination of nifedipine and beta-adrenergic blocking drugs may increase the likelihood of congestive heart failure, severe hypotension, or exacerbation of angina in patients with cardiovascular disease.

Digoxin: Since there have been isolated reports of patients with elevated digoxin levels, and there is a possible interaction between digoxin and ADALAT CC, it is recommended that digoxin levels be monitored when initiating, adjusting, and discontinuing ADALAT CC to avoid possible over- or under-digitalization.

Coumarin Anticoagulants: There have been rare reports of increased prothrombin time in patients taking coumarin anticoagulants to whom nifedipine was administered. However, the relationship to nifedipine therapy is uncertain.

Quinidine: There have been rare reports of an interaction between quinidine and nifedipine (with a decreased plasma level of quinidine).

Cimetidine: Both the peak plasma level of nifedipine and the AUC may increase in the presence of cimetidine. Ranitidine produces smaller non-significant increases. This effect of cimetidine may be mediated by its known inhibition of hepatic cytochrome P-450, the enzyme system probably responsible for the first-pass metabolism of nifedipine. If nifedipine therapy is initiated in a patient currently receiving cimetidine, cautious titration is advised.

Carcinogenesis, Mutagenesis, Impairment of Fertility: Nifedipine was administered orally to rats for two years and was not shown to be carcinogenic. When given to rats prior to mating, nifedipine caused reduced fertility at a dose approximately 30 times the maximum recommended human dose. *In vivo* mutagenicity studies were negative.

Pregnancy: Pregnancy Category C. In rodents, rabbits and monkeys, nifedipine has been shown to have a variety of embryotoxic, placental toxic and fetotoxic effects, including stunted fetuses (rats, mice and rabbits), digital anomalies (rats and rabbits), rib deformities (mice), cleft palate (mice), small placentas and underdeveloped chorionic villi (monkeys), embryonic and fetal deaths (rats, mice and rabbits), prolonged pregnancy (rats, not evaluated in other species), and decreased neonatal survival (rats, not evaluated in other species). On a mg/kg or mg/m² basis, some of the doses associated with these various effects are higher than the maximum recommended human dose and some are lower, but all are within an order of magnitude of it.

The digital anomalies seen in nifedipine-exposed rabbit pups are strikingly similar to those seen in pups exposed to phenytoin, and these are in turn similar to the phalangeal deformities that are the most common malformation seen in human children with *in utero* exposure to phenytoin.

There are no adequate and well-controlled studies in pregnant women. ADALAT CC should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.

Nursing Mothers: Nifedipine is excreted in human milk. Therefore, a decision should be made to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother.

ADVERSE EXPERIENCES: The incidence of adverse events during treatment with ADALAT CC in doses up to 90 mg daily were derived from multi-center placebo-controlled clinical trials in 370 hypertensive patients. Atenolol 50 mg once daily was used concomitantly in 187 of the 370 patients on ADALAT CC and in 64 of the 126 patients on placebo. All adverse events reported during ADALAT CC therapy were tabulated independently of their causal relationship to medication.

The most common adverse event reported with ADALAT CC was peripheral edema. This was dose related and the frequency was 18% on ADALAT CC 30 mg daily, 22% on ADALAT CC 60 mg daily and 29% on ADALAT CC 90 mg daily versus 10% on placebo.

Other common adverse events reported in the above placebo-controlled trials include: Headache (19%, versus 13% placebo incidence); Flushing/heat sensation (4%, versus 0% placebo incidence); Dizziness (4%, versus 2% placebo incidence); Fatigue/asthenia (4%, versus 4% placebo incidence); Nausea (2%, versus 1% placebo incidence); Constipation (1%, versus 0% placebo incidence).

Where the frequency of adverse events with ADALAT CC and placebo is similar, causal relationship cannot be established.

The following adverse events were reported with an incidence of 3% or less in daily doses up to 90 mg:

Body as a Whole/Systemic: chest pain, leg pain **Central Nervous System:** paresthesia, vertigo **Dermatologic:** rash **Gastrointestinal:** constipation **Musculoskeletal:** leg cramps **Respiratory:** epistaxis, rhinitis **Urogenital:** impotence, urinary frequency

Other adverse events reported with an incidence of less than 1.0% were:

Body as a Whole/Systemic: cellulitis, chills, facial edema, neck pain, pelvic pain, pain **Cardiovascular:** atrial fibrillation, bradycardia, cardiac arrest, extrasystole, hypotension, palpitations, phlebitis, postural hypotension, tachycardia, cutaneous angiectases **Central Nervous System:** anxiety, confusion, decreased libido, depression, hypertonia, insomnia, somnolence **Dermatologic:** pruritus, sweating **Gastrointestinal:** abdominal pain, diarrhea, dry mouth, dyspepsia, esophagitis, flatulence, gastrointestinal hemorrhage, vomiting **Hematologic:** lymphadenopathy **Metabolic:** gout, weight loss **Musculoskeletal:** arthralgia, arthritis, myalgia **Respiratory:** dyspnea, increased cough, rales, pharyngitis **Special Senses:** abnormal vision, amblyopia, conjunctivitis, diplopia, tinnitus **Urogenital/Reproductive:** kidney calculus, nocturia, breast engorgement

The following adverse events have been reported rarely in patients given nifedipine in other formulations: allergic hepatitis, alopecia, anemia, arthritis with ANA (+), depression, erythromelalgia, exfoliative dermatitis, fever, gingival hyperplasia, gynecostoma, leukopenia, mood changes, muscle cramps, nervousness, paranoid syndrome, purpura, shakiness, sleep disturbances, syncope, taste perversion, thrombocytopenia, transient blindness at the peak plasma level, tremor and urticaria.

PZ500046BS

9/96

© 1996 Bayer Corporation

6705

Printed in USA

References:

1. Glasser SP, Ripa SR, Allenby KS, Schwartz LA, Commins BM, Jungerwirth S, on behalf of the Nifedipine Study Group. The Efficacy and Safety of Once-Daily Nifedipine Administered without Food: The Coat-Core Formulation Compared with the Gastrointestinal Therapeutic System Formulation in Patients with Mild-to-Moderate Hypertension. *Clin Ther.* 1995;17(2):296-312.
2. Glasser SP, Jain A, Allenby KS, Shannon T, Pride K, Pettis PP, Schwartz L, MacCarthy EP, and the Nifedipine Study Group. The Efficacy and Safety of Once-Daily Nifedipine: The Coat-Core Formulation Compared with the Gastrointestinal Therapeutic System Formulation in Patients with Mild-to-Moderate Diastolic Hypertension. *Clin Ther.* 1995;17(1):12-29.
3. Data on file. Bayer Corporation, Pharmaceutical Division.
4. Zidek W, Spiecker C, Knaup G, Steindl L, Breuer H W, on behalf of the Hypertension Study Group. Comparison of the Efficacy and Safety of Nifedipine Coat-Core Versus Amlodipine in the Treatment of Patients with Mild-to-Moderate Essential Hypertension. *Clin Ther.* 1995;17(4):686-700.
5. *Redbook Update.* Montvale, NJ, Medical Economics Data, Inc., December 1996.
6. Adalat[®] CC Product Monograph, April 1995.

Bayer 

Pharmaceutical
Division

Bayer Corporation
Pharmaceutical Division
400 Morgan Lane
West Haven, CT 06516 USA
Made in U.S.A. and Germany

Classified Advertisements

The rate for each insertion is **\$9 per line** (six words per line) with **five lines (\$45) minimum**. Confidential box number charge: \$10 each month.

Classified display rate \$70 per inch. Maximum sizes: **1 column by 5 inches or 2 columns by 2 inches (2 1/8 inches per column).** Larger classified ad space by special arrangements.

Copy for classified advertisements should be received not later than **first of the month preceding issue.** All copy must be typed or printed. Classified advertisers using Box Numbers forbid the disclosure of their identity; your inquiries in writing will be forwarded to Box Number advertisers. Although *The Western Journal of Medicine* believes the classified advertisements in these columns to be from reputable sources, we do not investigate the offers made and assume no liability concerning them. The right is reserved to reject, withdraw, or modify all classified advertising copy in conformity with the decisions of the Advertising Committee.

Please Type or Print Advertising Copy

Classified Advertisements Are Payable in Advance

CLASSIFIED ADVERTISEMENTS
THE WESTERN JOURNAL OF MEDICINE
1224 WEST MAIN STREET, SUITE 200
CHARLOTTESVILLE, VA 22903-2858
(804) 979-8034; FAX (804) 979-4025
www.wjmed.com

PHYSICIANS WANTED

GASTROENTEROLOGY

The Division of Gastroenterology and the Department of Internal Medicine, at the UC Davis Medical Center, seek a full-time Chief of Hepatology. Appointment will be at Assistant/Associate Professor level commensurate with credentials. Candidate must be Board Certified in Internal Medicine and Gastroenterology with subspecialty interest in hepatology. Additionally, individual must be certified by United Network of Organ Sharing as a transplant physician. Candidate must possess M.D. degree and eligible for licensure in the State of California. Duties will include: patient care in both in-patient and out-patient clinical settings, clinical research, and teaching of medical students, interns, residents, and groups within community. Additional responsibilities will include administration of Section of Hepatology as well as active participation in UC Davis Liver Transplant Program, including coverage of transplant service in conjunction with transplant hepatology group. Candidates should submit a letter outlining research and teaching background, curriculum vitae, and five professional references to:

Joseph Leung, M.D., FRCP
Division of Gastroenterology
University of California, Davis Medical Center
Attn: Chief of Hepatology Search
4301 "X" Street, Room 2040
Sacramento, CA 95817

Applications accepted until position is filled but no later than September 30, 1997. UC Davis is an Affirmative Action/Equal Opportunity Employer.

PHYSICIANS WANTED

PRIMARY CARE

OREGON

Northwest Permanente, P.C., a professional group of physicians providing medical services to 400,000 members of Kaiser Permanente in Oregon and Southwest Washington, has opportunities in general family practice for BC/BE Family Physicians in Salem, OR and Internists in Portland and Salem, OR. Our program offers a professionally stimulating environment, a quality lifestyle in the Pacific Northwest and a competitive salary/benefits package. Forward inquiry and C.V. to: W.J. Weiland, M.D., Regional Medical Director, NORTHWEST PERMANENTE, P.C., 500 NE Multnomah Street, Suite 100, Portland, OR 97232-2099. EOE.



MAKE WAVES!

NEPHROLOGISTS! Hawaii, California, Arizona.
Heart Surgeon - AZ. Med Dir - E. Oregon.
Rheum; IM--ColumRiver, WA--\$135K;
InfectDis. & IM. IM/FP--Sacramento;
Seattle; Ortho--St. Louis or GUAM--\$200K
Not J-1/H-1 jobs. CV's:

LAM Associates, Dept W, 444 Hobron Ln, #207H,
Honolulu, HI 96815-1229.
Oahu PH: 808 947-9815.
Call Pat Lam, 10:30am-8pm PST: 1-800-258-4526.

pacific northwest

Placement specialists serving Northern California, Oregon, Washington. City or rural, group or solo. Internal Medicine, Family Practice, OB/GYN, Pediatrics, and all other specialties. No J-1 positions.

Barbara Stoen, President, THE O'KANE GROUP
25 NW Minnesota Ave, Ste 7, Bend, OR 97701
(800) 451-0700 • FAX (541) 389-5134
stoenf@empnet.com

WESTERN STATES OPENINGS

Many multispecialty groups and hospitals have asked us to recruit for over 100 positions of various specialties. Both permanent and locum tenens. Send CV to:

Western States Physician Services
7510 No. Trellis Circle, Fresno, CA 93720
Call (800) 873-0786; FAX (800) 705-7943
email: weserve@lightspeed.net

PHYSICIANS WANTED

Make One Of America's Best Places to Live Even Better.

Come to work here.

Primary Health, Idaho's largest integrated health care system, has a tremendous opportunity for Board-Certified Family Practitioners.

Where You'll Work.

Primary Health is Idaho's largest, fastest growing integrated health care system with offices throughout southern Idaho. We're looking for quality physicians with an independent spirit who want the freedom to help people get well and stay well.

Where You'll Live.

Southern Idaho, a great place to raise a family with low crime rates, incredible outdoor recreation like downhill and cross-country skiing, fishing, hunting, universities and colleges, professional basketball and baseball, 10-minute commutes, top quality schools and excellent hospitals.

What You'll Get.

The financial backing and medical resources of a major health care network. A competitive salary package, ownership options, flexible work and call schedules, professional growth opportunities, full benefits package including medical and dental coverage, the chance to take care of people rather than your business and much more.

Submit CV and questions to:

Becky Nelson
(800) 688-5008 ext. 507
FAX (208) 344-4262

Physician Recruitment
800 Park Boulevard, Suite 760
Boise, Idaho 83712



Since 1979
the



LOCUM TENENS NETWORK has been taking the hassles of the paperwork and overhead out of practicing medicine. Practice near home or travel the country. We will coordinate all your travel details and provide you with the best occurrence malpractice policy available. Explore a partnership with Interim Physicians and open new horizons for your future.

Call today! (800) 333-7828

- PLAN B -

Do you want to earn some extra money? Are you willing to set aside 6 to 10 hours per week? If so, call Fares Arguello, MD 801-484-6686.

CENTRAL WASHINGTON STATE

Two openings in wine country of Washington State. DO/FP with OMT, and FP with OB.

Call (800) 548-7086 ext. 624, or visit our website at televar.com/sch.

LIFESTYLE IS EVERYTHING!

Offering the best lifestyle and practice opportunities from Washington to California to Florida. We need primary care BC/BE MD's and DO's for permanent and locum tenens positions. We have civilian positions available at military installations. CALL US or Fax CV Today!

Catalina Professional Recruiters
Tucson 800-658-9166 Fax 520-733-4678
Phoenix 800-657-0354
Visit us at <http://www.catrctr.com>

PHYSICIANS WANTED

PRIMARY CARE INTERNIST - The Everett Clinic, a 140 physician multispecialty group, is seeking BC/BE internist to associate with 17 person department. Position located at a satellite office. The main clinic is 25 miles north of Seattle and has 6 rapidly expanding satellite offices. Opportunity for exceptional personal/professional lifestyle. Position offers competitive salary with excellent benefits. Available 1997. Not a J-1 position. Send CV to J.G. Finley, MD, Medical Director, The Everett Clinic, 3901 Hoyt Avenue, Everett, WA 98201

OREGON AND THE NORTHWEST. Urban, suburban, rural locations; variety of practice arrangements; all specialties. Placement professionals for 20 yrs. Oberto & Associates, 920 Pinecrest Terr, Ashland, OR 97520. (800) 482-6656; FAX (541) 482-4951. No J-1 Opp.

CALIFORNIA - Emergency Medicine/Family Practice-California Emergency Physicians Medical Group is a partnership of Emergency Medicine and ambulatory care specialists contracting with over 35 Emergency depts and 10 ambulatory care centers in Northern, Central, and Southern California. We are seeking BC/BP Emergency Medicine and Family Practice Physicians. We offer attractive compensation, ownership, health, disability, and retirement benefits. Send your CV or contact John Gravette, CEP, 2101 Webster Street, Suite 1050, Oakland, CA 94612; (800) 842-2619.

Medical Physician. General Family Practitioner or Internist for Multi Disciplinary Spine, Occupational, Family Clinic. Must have knowledge of alternative health care. Orem UT (801) 224-3413.

INTERNAL MEDICINE - NORTHERN CALIFORNIA - Located in Sierra Foothills between San Francisco and Lake Tahoe. Five person, high quality, fee-for-service, Internal Medicine group seeks a replacement internist to take over practice of a member who is leaving. Group members all originally from upper Midwest. Work four days/week with every fifth night on call and every fifth weekend. Does not qualify for J-1. Call Gary Woodward, M.D. (209) 233-3837 or write to 815 Court Street, Suite #7, Jackson, CA 95642.

CALIFORNIA

**LOCUM TENENS
PERMANENT PLACEMENTS**

Jim Ellis (800) 437-7676

**WJM Classifieds
Online**

www.wjmed.com

**Searchable by ad type,
location, and specialty.
Updated regularly.**

PHYSICIANS WANTED

**LOCUM TENENS
PERMANENT PLACEMENT**

**TRACY ZWEIG
ASSOCIATES**

**A Physician Registry and
Placement Firm**

(805) 641-9141 • (800) 919-9141

FAX (805) 641-9143

e-mail: tzweig@isle.net

**Occupational and Environmental
Medicine**

The University of California, San Francisco is recruiting for part-time Associate Physicians for the Division of Occupational and Environmental Medicine. Career and casual positions with variable schedules are available. The candidates will participate in the clinical activities of the Occupational Medicine Clinics at UCSF/Mount Zion Medical Center or San Francisco General Hospital. Professional duties include treating job injuries and performing screening examinations for workers with occupational exposures. Applicants must possess a license to practice medicine in California, Board-certified/eligible in Occupational Medicine, Orthopaedic Surgery, Internal Medicine or Family Practice preferred. UCSF is an affirmative action/equal opportunity employer.

The University undertakes affirmative action to assure equal employment opportunity for underutilized minorities and women, for persons with disabilities, and for Vietnam-era veterans and special disabled veterans.

Please send inquiries and CV to Ira Lezcano, Box 0843, University of California, San Francisco, San Francisco, CA 94143.

OFFICE SPACE AVAILABLE

Los Angeles Area

Office space available in the Doctors Towers adjacent to Queen of Angels—Hollywood Presbyterian Medical Center. Full amenities. Will build to suit tenant. Medical suites to share also available. On-site manager.

Call (213) 913-4911

PHYSICIANS WANTED

**Faculty Physician
in Clinical Nutrition**

The Division of Clinical Nutrition and Metabolism at the University of California, Davis is recruiting a full-time faculty physician who is board certified in Internal Medicine and has had subspecialty training in Clinical Nutrition or a related field. Responsibilities will include inpatient and outpatient clinical care, teaching and a commitment to clinical research.

Candidate must be eligible for licensure in the State of California. The appointment will be at the assistant/associate level commensurate with qualifications. Position is "open until filled, but not later than December 31, 1997." Please send letter of interest, CV, and names and addresses of three references to:

Charles H. Halsted, M.D.
Chair, Faculty Search Committee (#1561)
Division of Clinical Nutrition & Metabolism
University of California
Davis, CA 95616

UCDAVIS

UCD is an Equal Opportunity/Affirmative Action Employer

Director, Student Health Services

The California State University San Marcos seeks full-time physician to provide leadership and direction to a multidisciplinary staff of health care professionals. The incumbent will participate in direct supervision of the medical clinic's operations, coordinate campus-based services and represent health matters on campus.

Must demonstrate experience in the application of principles and techniques of primary medical care, diagnostic treatments and medical counseling, analyze emergency situations and supervise the work of professional and ancillary personnel. Knowledge of ambulatory care clinic accreditation processes.

MD degree required. Three years of equivalent or increasingly responsible experience in a n ambulatory health care setting. Prior experience in a Student Health Services university setting highly preferred. Board Certification or eligibility in a primary care specialty or preventive medicine and current California medical license.

Salary commensurate with education and experience.

The search committee will begin to review applications for the position on June 9, 1997. Qualified applicants should submit a completed CSUSM Employment application and three references to:

Human Resources Management
REF: Director, Student Health Services, REQ #494
California State University, San Marcos
San Marcos, CA 92096-0001

e-mail: human_resources@csusm.edu

CSU San Marcos is an AA/EO Title IX Employer

CASE STUDY TOPICS

Acute Inferior Myocardial Infarction

Atrial Fibrillation

Aortic Stenosis

Angina/Coronary Artery Disease

CARDIOLOGY

Interactive CME
CD-ROM for Primary
Care Physicians


RALPH S. BUCKLEY, MD
LAWRENCE W. GIMPLE, MD

UNIVERSITY OF VIRGINIA OFFICE OF
CONTINUING MEDICAL EDUCATION

 Earn 6 valuable hours of AMA Category I CME Credit at your own pace

 Explore cardiovascular disease in ways only available through the power of multimedia

 Sharpen your patient diagnostic and management skills through realistic case studies designed for the Primary Care physician

 Experience actual EKGs, animated 3-D heart models, full-motion echocardiography and cineangiography, and other diagnostic information in a realistic patient setting

Learn to recognize and manage cardiovascular disease in a realistic patient setting. This interactive CD-ROM provides a comprehensive overview of cardiovascular disease, including the latest diagnostic and management techniques.

Learn to recognize and manage cardiovascular disease in a realistic patient setting. This interactive CD-ROM provides a comprehensive overview of cardiovascular disease, including the latest diagnostic and management techniques.

REQUIREMENTS

SYSTEM

MACINTOSH

Recommended:

- Color-capable Macintosh computer using a 68040 25 MHz processor or better, including Powerbook and PowerPC™
- Color monitor and video card supporting thousands of colors at 640x480
- 12 MB RAM
- System 7.01 or later
- QuickTime™ 2.5 (included)
- 4X CD-ROM drive
- Stereo headphones or speakers
- 12MB hard disk space
- Mouse or appropriate replacement

WINDOWS AND WINDOWS 95

Recommended:

- 66 MHz Pentium processor or better
- 12MB RAM
- 4X CD-ROM drive
- SVGA 640x480 monitor supporting true color
- Microsoft® Windows 3.x, Windows 95, Windows NT 3.5.1 or later
- QuickTime™ 2.1 for Windows (included)
- Stereo headphones or speakers
- Minimum 12MB free disk space
- Mouse or appropriate replacement
- Minimum MPC-Level 1 compatible sound card

Please send _____ copies of *Cases in Cardiology*™ at the price of \$99.00 each, plus \$5.00 shipping and handling.

Name: _____

Institution: _____

Address: _____

City: _____ State: _____ Zip: _____

Country: _____

Phone: _____ Fax: _____

E-mail: _____

Medical Specialty: _____

Payment preference: ☐ Bill me ☐ Check enclosed
☐ VISA ☐ MasterCard

Name on Card: _____

Card #: _____ Exp. Date: _____

Signature: _____

Return to: Carden Jennings Publishing Co., Ltd.
1224 West Main Street, Suite 200
Charlottesville, VA 22903

phone: (804) 979-4208 fax: (804) 979-4025
Internet: www.cardiocases.com



© COPYRIGHT 1996 CARDEN JENNINGS
PUBLISHING CO., LTD. ALL RIGHTS RESERVED.